Aardvark Therapeutics, Inc. (AARD)

NMS – Real vaqt narxi. Valyuta: USD

6.11

+0.39 (6.82%)

Yopilishda: May 12, 2026, 4:00 PM EDT

5.99

-0.12 (-1.96%)

Bozordan keyin: May 12, 2026, 7:18 PM EDT

07.05.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

07.05.2026

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates. “We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,” said Tien Lee, M.D.

28.04.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome (“PWS”). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

22.04.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

SAN FRANCISCO, April 22, 2026 /PRNewswire/ - On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

14.04.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome (“PWS”). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

10.04.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

SAN FRANCISCO, April 10, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

09.04.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

SAN FRANCISCO, April 09, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome (“PWS”). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

07.05.2026

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

28.04.2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

22.04.2026

Aardvark Therapeutics, Inc. (AARD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Videolar

No Data

Press-relizlar

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Videolar

No Data

Press-relizlar

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Search stocks

Aardvark Therapeutics, Inc. (AARD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Videolar

No Data

Press-relizlar

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Videolar

No Data

Press-relizlar

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman